Loading...
•
Mar 31
Chemours Q1 2025 Earnings Report
Reported First Quarter 2025 Results
Key Takeaways
The Chemours Company reported net sales of $1.4 billion in the first quarter of 2025, in line with the prior-year quarter. The company experienced a net loss of $4 million, or $0.03 per diluted share, compared to net income of $54 million in the prior-year quarter. Adjusted EBITDA decreased by 13% year-over-year.
Net Sales in Q1 2025 were $1.4 billion, consistent with Q1 2024.
The company reported a Net Loss of $4 million in Q1 2025, a significant decrease from Net Income of $54 million in Q1 2024.
Adjusted EBITDA for Q1 2025 was $166 million, down 13% from $191 million in Q1 2024.
Free cash flow for Q1 2025 was a use of $196 million, an improvement compared to a use of $392 million in Q1 2024.
Chemours
Chemours
Chemours Revenue by Segment
Revenue by Segment
Thermal & Specialized Solutions Revenue
CapyFin.comTitanium Technologies Revenue
CapyFin.comAdvanced Performance Materials Revenue
CapyFin.comOther Non-Reportable Segment Revenue
CapyFin.com Forward Guidance
For the second quarter of 2025, Chemours anticipates sequential increases in consolidated Net Sales and Adjusted EBITDA. Full-year 2025 Adjusted EBITDA is expected to range between $825 million and $950 million, with capital expenditures between $225 million and $275 million.
Positive Outlook
- Consolidated Net Sales expected to increase in the low to mid-teens sequentially in Q2 2025.
- Consolidated Adjusted EBITDA expected to increase by 40% to 45% sequentially in Q2 2025.
- TSS segment expects sequential Net Sales increase in the low 20% range in Q2 2025.
- TT segment expects sequential Net Sales increase in the high single-digits in Q2 2025.
- APM segment expects sequential Net Sales increase in the low-teens in Q2 2025.
Challenges Ahead
- Corporate Expenses are expected to decrease only in the low single-digits sequentially in Q2 2025.
- Free cash flow in the second quarter is expected to be only slightly positive.
- Full-year 2025 Adjusted EBITDA guidance range is wide ($825 million to $950 million).
- Full-year 2025 capital expenditures are projected to be significant ($225 million to $275 million).
- The outlook assumes existing tariff environment and no larger indirect impacts from tariffs or recessionary impacts.